.Pharmacolibrary.Drugs.ATC.R.R05CB05

Information

Mesna (sodium 2-mercaptoethane sulfonate) is a protective agent used to reduce the occurrence of hemorrhagic cystitis and other urogenital toxicities in patients receiving ifosfamide or cyclophosphamide chemotherapy. It is an FDA-approved medication commonly administered alongside these alkylating agents.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after intravenous administration.

References

1. Mastrangelo, S, et al., & Mastrangelo, R (2001). Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. British journal of cancer 84(4) 460–464. DOI:10.1054/bjoc.2000.1645 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11207038

2. van Warmerdam, LJ, et al., & Beijnen, JH (1994). Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer chemotherapy and pharmacology 35(2) 179–181. DOI:10.1007/BF00686644 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7987998

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)